Kestra Medical reports post‑approval study meets safety and effectiveness goals
Kestra Medical Technologies announced that its ASSURE Wearable Cardioverter Defibrillator post‑approval study, ACE‑PAS, enrolled 21,612 patients and achieved 100% shock conversion for all 303 analyzable ventricular tachycardia/fibrillation events. The study met its primary safety target with an inappropriate‑shock rate of 0.0065 per patient‑month and 94% of patients experiencing no false‑positive alarms. Kestra said an enhanced detection algorithm introduced in April 2026 should cut the inappropriate‑shock rate by nearly 70% to about 0.0020 per patient‑month.
Why it matters
The company notes that commercial impact will depend on adoption and sales growth, implying that the positive results could support broader market uptake of the ASSURE system.
Key facts
- 1The ACE‑PAS study enrolled 21,612 patients across 35 U.S. states. investing.com
- 2All 303 analyzable ventricular tachycardia or ventricular fibrillation episodes were successfully converted, yielding 100% shock conversion success. investing.com
- 3The inappropriate‑shock rate was 0.0065 per patient‑month, meeting the prespecified safety goal. investing.com
- 494% of patients experienced no false‑positive shock alarms. investing.com
- 5Patients wore the device a median of 23.1 hours per day. investing.com
- 6Around 30% of patients continued use beyond 90 days while maintaining the same median daily wear time. investing.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.